Allergan stock looks attractive – Barron’s

NEW YORK, May 16 (BestGrowthStock) – Allergan Inc (AGN.N: ), the
maker of Botox, is set to reap the rewards of an aging
population, financial weekly Barron’s said in its May 17

Allergan’s stock trade at around $61 — 17 times projected
2011 profits. Drug companies sell for 10 times earnings, but
cannot match Allergan’s 19 percent profit margins, according to

Allergan bought the rights to Botox in 1988 for $9 million.
Today it is worth $1.3 billion, and this could grow if
regulators approve the product for treating migraine headaches.
Wells Fargo said there was a 60 percent chance regulators would
approve it in July, Barron’s said.

The company also produces skin-care treatments, which saw a
32 percent boost in sales during the first quarter of 2010.

Stock Market News

(Reporting by Helen Kearney, editing by Maureen Bavdek)

Allergan stock looks attractive – Barron’s